Lipid ‐lowering therapy with PCSK9‐inhibitors in the real‐world setting: Two‐year experience of a regional lipid clinic

ConclusionsPatient selection by a regional lipid clinic resulted in a high real ‐world PCSK9i insurance approval, with efficacy and safety comparable to randomized clinical trials. Cost and medication nonadherence are potential barriers to successful implementation of therapy in routine clinical care.

Source: Cardiovascular Therapeutics - September 12, 2018 Category: Cardiology Authors: Barak Zafrir, Ayman Jubran Tags: ORIGINAL RESEARCH ARTICLE Source Type: research